Development and validation of HPLC-FLD method for simultaneous determination of ternary therapy used for COVID-19 in plasma samples

Abstract

A novel green sensitive micellar HPLC method with fluorescence detection is introduced for the analysis of remdesivir, levodropropizine, and moxifloxacin hydrochloride as ternary therapy for COVID-19 in human plasma samples using losartan as internal standard. The separation was carried out on Hypersil BDS C18 column using a mixed micellar mobile phase of sodium lauryl sulfate (SLS), Polyoxyethylene (23) lauryl ether (Brij-35) adjusted to pH 6. For enhanced specificity, a fluorescence detector was set to 246ex/403em for remdesivir, 296ex/504em for moxifloxacin hydrochloride , 252ex/342em for levodropropizine, and 252ex/316em for Losartan. The method showed a linear response within the concentration ranges of 80-2000 ng/mL for remdesivir and moxifloxacin hydrochloride and 160-4000 ng/mL for levodropropizine showing high accuracy and precision. The current study's significance lies in the development of a highly sensitive and selective analytical method for the simultaneous determination of three different drugs (remdesivir, moxifloxacin hydrochloride, and levodropropizine) in spiked human plasma, using an economical sample preparation strategy. Eco scale, GAPI and AGREE confirmed the greenness of the method which shows the least impact on the environment along with high score for eco-friendliness. This creates a new approach for routine quality control and pharmacokinetic research of remdesivir, levodropropizine and moxifloxacin hydrochloride.